02:41 PM EDT, 08/19/2024 (MT Newswires) -- Genmab ( GMAB ) said Monday that the European Commission granted conditional approval for Tepkinly, or epcoritamab, for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Tepkinly, codeveloped with AbbVie ( ABBV ) , is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more prior treatments in the European Union as well as Iceland, Liechtenstein, Norway and Northern Ireland.

The expanded approval is based on data from Epcore NHL-1 study that showed an overall response rate of 83% in patients getting Tepkinly as third-line treatment.

Genmab ( GMAB ) shares were up over 2% in recent trading, while that of AbbVie ( ABBV ) were up more than 1%.

Price: 27.58, Change: +0.63, Percent Change: +2.34